A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease | Zendy

Audrey Bennett | Zendy; Lauren E. Carlini | Zendy; Caroline Duley | Zendy; Ailish Garrett | Zendy; Kim Annis | Zendy; Julianne Wag | Zendy; Robin Dalal | Zendy; Elizabeth Scoville | Zendy; Dawn B. Beaulieu | Zendy; David A. Schwartz | Zendy; Sara N. Horst | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease

Author(s) -

Audrey Bennett,

Lauren E. Carlini,

Caroline Duley,

Ailish Garrett,

Kim Annis,

Julianne Wag,

Robin Dalal,

Elizabeth Scoville,

Dawn B. Beaulieu,

David A. Schwartz,

Sara N. Horst

Publication year - 2020

Publication title -

crohn s and colitis 360

Language(s) - English

Resource type - Journals

ISSN - 2631-827X

DOI - 10.1093/crocol/otaa013

Subject(s) - ustekinumab , medicine , refractory (planetary science) , crohn's disease , single center , gastroenterology , retrospective cohort study , surgery , disease , adalimumab , physics , astrobiology

Background Ustekinumab was approved for moderate and severe Crohn’s disease (CD) in 2016, but little is known about long-term outcomes. Methods A retrospective study evaluated all patients with CD treated with ustekinumab, including patients with reinduction. C-reactive protein (CRP), Harvey-Bradshaw Index (HBI), Short Inflammatory Bowel Disease (SIBDQ), and endoscopy outcomes were collected prospectively. Results Ninety-six patients received ustekinumab, resulting in improvement in CRP, HBI, and SIBDQ scores with 68% endoscopic improvement/remission. Thirty-four patients underwent reinduction, resulting in improved HBI and CRP. Conclusions Ustekinumab in refractory CD results in significant clinical and endoscopic improvement and reinduction may be a viable option to recapture response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research